Welcome to our dedicated page for Sionna Therapeutics news (Ticker: SION), a resource for investors and traders seeking the latest updates and insights on Sionna Therapeutics stock.
Sionna Therapeutics, Inc. (Nasdaq: SION) is a clinical-stage biopharmaceutical company focused on cystic fibrosis, and its news flow reflects ongoing progress in this specialized area of drug development. Company announcements frequently describe advances in its pipeline of small molecule nucleotide binding domain 1 (NBD1) stabilizers and complementary CFTR modulators designed to improve CFTR protein function.
News items for SION often cover key clinical milestones, such as initiation of the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis, and the Phase 1 trial assessing SION-451 in dual combinations with SION-2222 and SION-109 in healthy volunteers. Updates may include information on trial design, target patient populations, measures of CFTR function such as sweat chloride levels, and the rationale for combining NBD1 stabilizers with existing therapies.
Investors and observers can also find press releases on Phase 1 data, including reports that SION-719 and SION-451 were generally well tolerated and exceeded target exposure levels, as well as preclinical findings that NBD1 stabilizers increased the half-life of F508del-CFTR protein to levels seen with wild-type CFTR. Additional news highlights Sionna’s participation in scientific meetings like the North American Cystic Fibrosis Conference and appearances at healthcare and investor conferences.
This SION news page aggregates these disclosures, allowing readers to follow developments in Sionna’s CF-focused programs, track clinical and preclinical data releases, and monitor corporate updates that the company furnishes through press releases and related communications.
Sionna Therapeutics (Nasdaq: SION) reported topline data from two cystic fibrosis programs and provided a corporate update. The Phase 2a PreciSION CF trial of SION-719 added to Trikafta did not meet its key activity endpoint in sweat chloride reduction, and Sionna will not advance SION-719 as an add-on to standard of care.
The Phase 1 healthy volunteer trial of SION-451 dual combinations met safety, tolerability, and pharmacokinetic objectives, with SION-451 + SION-2222 selected as the preferred combination. According to Sionna, SION-719 and the dual regimens were generally well tolerated. The company ended Q2 with about $268.3 million in cash, cash equivalents, and marketable securities and plans to take actions to preserve capital while evaluating next steps for SION-451.
Sionna Therapeutics (Nasdaq: SION) reported second quarter 2026 results and clinical progress for its cystic fibrosis (CF) pipeline. The PreciSION CF Phase 2a proof-of-concept trial of NBD1 stabilizer SION-719 as an add-on to standard of care has completed enrollment and remains on track to deliver topline data in summer 2026, assessing safety, pharmacokinetics and CFTR function via sweat chloride.
The Phase 1 trial of NBD1 stabilizer SION-451 in proprietary dual combinations with CFTR correctors SION-2222 and SION-109 in healthy volunteers is also expected to report topline data this summer. According to Sionna, encore clinical and nonclinical data for SION-719 and SION-451 were presented at the 49th European Cystic Fibrosis Conference, showing nonclinical evidence that NBD1 stabilizers can increase F508del-CFTR protein half-life up to wild-type levels alone or with complementary modulators.
For the quarter ended June 30, 2026, research and development expenses were $21.9 million and general and administrative expenses were $10.6 million, leading to a net loss of $29.9 million (basic and diluted net loss per share of $0.66). Cash, cash equivalents and marketable securities totaled $268.3 million, which Sionna expects will fund operations into 2028.
Sionna Therapeutics (Nasdaq:SION), a clinical-stage biopharma focused on cystic fibrosis, will participate in two June 2026 investor conferences.
Management presents at the Jefferies Global Healthcare Conference on June 3, 2026, at 12:15 p.m. ET and a Goldman Sachs Global Healthcare fireside chat on June 10, 2026, at 10:00 a.m. ET. Live webcasts and replays will be available in the company’s Investors section online.
Sionna Therapeutics (Nasdaq:SION), a clinical-stage biopharmaceutical company focused on cystic fibrosis, will join the 2026 RBC Capital Markets Global Healthcare Conference.
Management will participate in a fireside chat on May 20, 2026 at 2:05 p.m. ET, with a live webcast and replay available via the company’s investor website.
Sionna Therapeutics (Nasdaq:SION) reported Q1 2026 results and CF pipeline progress. Enrollment in the PreciSION CF Phase 2a trial of SION-719 is complete, and a Phase 1 dual-combination trial of SION-451 is ongoing, with topline data for both expected in summer 2026.
Q1 2026 R&D expenses were $19.0M, G&A expenses $10.6M, and net loss $26.8M. Cash, cash equivalents and marketable securities totaled $289.9M at March 31, 2026, expected to fund operations into 2028.
Sionna Therapeutics (Nasdaq: SION) announced completion of enrollment in the PreciSION CF Phase 2a proof-of-concept trial testing SION-719, a first-in-class NBD1 stabilizer added to Trikafta® in adults homozygous for F508del. Topline data are anticipated in summer 2026.
The randomized, double-blind, placebo-controlled, crossover study will evaluate safety, tolerability, pharmacokinetics, and change in sweat chloride as a measure of CFTR function. The trial enrolled at multiple sites including the CF Foundation Therapeutics Development Network.
Sionna Therapeutics (Nasdaq: SION) said management will hold one-on-one investor meetings at the Raymond James 2026 Biotech Innovation Symposium on April 14, 2026. The meetings provide investor access to management to discuss clinical progress in cystic fibrosis programs and corporate strategy.
Sionna Therapeutics (Nasdaq: SION) reported fourth-quarter and full-year 2025 results and a pipeline update. Cash, cash equivalents and marketable securities totaled $310.3 million as of December 31, 2025, expected to fund operations into 2028.
Ongoing Phase 2a PreciSION CF trial of SION-719 and a Phase 1 dual-combination trial of SION-451 remain on track with topline data anticipated in mid-2026. Company reported higher net loss and increased general and administrative expenses for 2025.
Sionna Therapeutics (Nasdaq: SION) announced management will participate in investor fireside chats in March 2026. Events include TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 2:30 p.m. ET and Leerink Partners Global Healthcare Conference on March 10, 2026 at 1:40 p.m. ET.
Live webcasts and replays will be available in the Investors section at https://investors.sionnatx.com/.
Sionna Therapeutics (Nasdaq: SION) announced management will present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 2:00 p.m. ET. A live webcast and a replay will be available on Sionna's Investors "Events" page.
The presentation focuses on the company’s clinical-stage programs targeting normalization of CFTR function for cystic fibrosis.